Hope for swallowing relief: Year-Long drug trial targets severe esophagus scarring
NCT ID NCT06352073
Summary
This study is testing how well an already FDA-approved drug, dupilumab, works for people with a severe form of Eosinophilic Esophagitis (EoE) that causes dangerous narrowing of the esophagus. All 30 participants will receive weekly dupilumab injections under the skin for one year. Researchers will check if the drug reduces inflammation, improves the width of the esophagus, and decreases the need for painful stretching procedures.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EOSINOPHILIC ESOPHAGITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599, United States
Conditions
Explore the condition pages connected to this study.